Antihistone and Anti-double-stranded Deoxyribonucleic Acid Antibodies Are Associated with Renal Disease in Systemic Lupus Erythematosus
Overview
Authors
Affiliations
Purpose: We sought to assess the nephritogenic antibody profile of patients with systemic lupus erythematosus (SLE), and to determine which antibodies were most useful in identifying patients at risk of nephritis.
Methods: We studied 199 patients with SLE, 78 of whom had lupus nephritis. We assayed serum samples for antibodies against chromatin components (double-stranded deoxyribonucleic acid [dsDNA], nucleosome, and histone), C1q, basement membrane components (laminin, fibronectin, and type IV collagen), ribonucleoprotein, and phospholipids. Correlations of these antibodies with disease activity (SLE Disease Activity Index) and nephropathy were assessed. Patients with no initial evidence of nephropathy were followed prospectively for 6 years.
Results: Antibodies against dsDNA, nucleosomes, histone, C1q, and basement membrane components were associated with disease activity (P <0.05). In a multivariate analysis, anti-dsDNA antibodies (odds ratio [OR] = 6; 95% confidence interval [CI]: 2 to 24) and antihistone antibodies (OR = 9.4; 95% CI: 4 to 26) were associated with the presence of proliferative glomerulonephritis. In the prospective study, 7 (6%) of the 121 patients developed proliferative lupus glomerulonephritis after a mean of 6 years of follow-up. Patients with initial antihistone (26% [5/19] vs. 2% [2/95], P = 0.0004) and anti-dsDNA reactivity (6% [2/33] vs. 0% [0/67], P = 0.048) had a greater risk of developing proliferative glomerulonephritis than patients without these autoantibodies.
Conclusion: In addition to routine anti-dsDNA antibody assay, antihistone antibody measurement may be useful for identifying patients at increased risk of proliferative glomerulonephritis.
Clinical Profile and Outcomes of Patients With Systemic Lupus Erythematosus.
Bagare P, Borle A, Baluni P, Ekbote G, Sangale S Cureus. 2024; 16(9):e68541.
PMID: 39364459 PMC: 11448960. DOI: 10.7759/cureus.68541.
Sole C, Royo M, Sandoval S, Moline T, Gabaldon A, Cortes-Hernandez J Int J Mol Sci. 2024; 25(8).
PMID: 38673811 PMC: 11050013. DOI: 10.3390/ijms25084226.
Lupus Nephritis Biomarkers: A Critical Review.
Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).
PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.
Hsu T, Yang Y, Wang L, Lee J, Yu H, Lin Y Pediatr Rheumatol Online J. 2023; 21(1):28.
PMID: 36964531 PMC: 10039593. DOI: 10.1186/s12969-023-00806-x.
Choi S, Park D, Kang J, Lee S Ann Med. 2023; 55(1):1009-1017.
PMID: 36896834 PMC: 10795605. DOI: 10.1080/07853890.2023.2187076.